Form 4: Armata Director Granted 25,640 Stock Options

Armata Pharmaceuticals director Odysseas Kostas D received 25,640 stock options with an exercise price of $11.61, vesting in March 2027.

Summary

• Odysseas Kostas D, a Director of Armata Pharmaceuticals, Inc. (ARMP), acquired 25,640 stock options.
• The transaction date for the option grant was March 9, 2026.
• The exercise price for these stock options is $11.61 per share.
• The options will vest in full on March 9, 2027, contingent upon continuous service through that date.
• The expiration date for these stock options is March 9, 2036.
• Following this transaction, Odysseas Kostas D beneficially owns 25,640 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as it represents a standard practice for aligning director incentives with shareholder interests, without indicating any immediate operational or financial changes.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, as the options gain value if the stock price increases.
• The options have a long expiration date (March 9, 2036), providing a significant window for potential value realization.

Future Outlook

The stock options are subject to a future vesting condition on March 9, 2027, requiring continuous service through that date for the options to become fully exercisable.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including companies like Armata Pharmaceuticals. This compensation structure is designed to incentivize long-term performance and align the interests of board members with shareholder value creation, similar to practices seen at peers such as Moderna or BioNTech, where equity-based compensation forms a significant part of executive and director remuneration.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, a single cliff vest after one year, is a common approach for director equity grants, aiming to retain talent and ensure commitment over a defined period.
• The exercise price being set at the market price on the grant date is typical for incentive stock options, ensuring that the options only gain intrinsic value if the company's stock price appreciates.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor future dilution if exercised, but it also serves to align the director's financial interests with long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The stock options are scheduled to vest on March 9, 2027, provided the director maintains continuous service.

Key Dates

Keywords

Armata Pharmaceuticals, ARMP, Stock Options, Insider Transaction, Director Compensation, Form 4, Equity Grant